Vietnam: Ban from Ministry of Health vs. Piloting Management from Ministry of Industry and Commerce

Regulations by 2FIRSTS, edited by Sophia
May.05.2024
Vietnam: Ban from Ministry of Health vs. Piloting Management from Ministry of Industry and Commerce
Vietnam debates whether to ban or regulate e-cigarettes due to potential health risks and widespread use among youth.

According to Vietnamese media outlet Viettimes, on May 4th, the issue of whether to ban or regulate e-cigarettes was discussed in the National Assembly by the Social Affairs Committee and the National Assembly's Committee on Cultural Education to address concerns about the harm caused by e-cigarettes and heated tobacco products.

 

Deputy Minister of Health Dao Honglan stated that the Ministry of Health has already done a lot of work, providing advice to the national management through evidence and impact assessment in order to revise the Tobacco Harmful Effects Law and make plans. Minister of Industry and Trade Pan Sheng proposed piloting management of e-cigarettes.

 

Faced with the conflicting views of the Ministry of Health and the Ministry of Industry and Commerce on e-cigarettes, representatives in Congress raised pointed questions.

 

The Vice Chairman of the Vietnamese National Assembly, Tran Thanh Man, expressed concerns about the increasing prevalence of e-cigarette use, especially among young people, teenagers, and students, which are gradually replacing traditional tobacco. He emphasized that the health risks of e-cigarettes are similar to traditional tobacco, particularly the harm they pose to the brain development of children and adolescents, leading to addiction, cognitive and emotional disorders, reduced learning abilities, and psychological obstacles. E-cigarettes also have a negative impact on the quality of human resources, affecting social order and economic and social development.

 

Vice Chairperson of the Cultural and Education Committee, Ms. Ruan Mei, calls for clarity on the boundaries between the economic benefits of e-cigarettes and the negative impacts on health costs.

 

Speaking at the conference, Dr. Nguyen Vinh Chi firmly stated, "I find it strange, why test addictive substances, especially such deadly substances. There is absolutely no need for any testing! Because e-cigarettes have already proliferated globally and in Vietnam, their harm is widely recognized... As a doctor, I question whether anyone can find any benefits of this e-cigarette!"

 

Dao Honglan emphasized that e-cigarettes and heated tobacco products pose great risks to human health, and therefore should be banned from the start rather than being allowed on the market before becoming unmanageable. Even with the various current methods of e-cigarette regulation, the question of whether they can be effectively managed is a concerning issue. Who will be responsible for people's lives? Especially when around 40,000 people die from smoking each year.

 

Deputy Director Chen Ruanquan, of the Legal and Administrative Reform Department of the Ministry of Public Security, shares the same view as the Ministry of Health, believing that e-cigarettes pose a harm to human health, particularly for young people. He maintains that this product not only harms human health but also the economy. In particular, individuals who have been convicted of drug offenses are increasingly using e-cigarettes to soak and mix drugs.

 

Teenage use of e-cigarettes is widespread. People are always seen using e-cigarettes while waiting at red lights on the streets. This trend is growing at a concerning rate, so the harms of e-cigarettes outweigh the expected economic and social benefits, according to Rear Admiral Chen Ruanquan.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
China’s State Council has appointed Zhang Xiaotang as deputy director of the State Tobacco Monopoly Administration, with the regulator’s official website now listing him as a Party leadership group member and deputy director. Zhang previously led Hebei China Tobacco and earlier headed the STMA’s finance and audit department. His appointment follows the elevation earlier this year of former tax official Yao Laiying to head the STMA, adding another senior official with a strong fiscal or financial-management background to China Tobacco’s top leadership in 2026.
News
Sep.20
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-founded online nicotine pouch retailer GotPouches has completed the localization of its U.S. operations under UpNorth Retail LLC, with corporate operations in Franklin, Tennessee, domestic fulfillment from Nashville and U.S.-based customer support. The company says its catalog covers more than 20 nicotine pouch brands and it currently serves customers in more than 25 U.S. states.
Sep.18
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
Product | KT&G Launches lil HYBRID 3.0 Misty Rosé Edition II in South Korea With Two Pink Finishes at 88,000 Won
Product | KT&G Launches lil HYBRID 3.0 Misty Rosé Edition II in South Korea With Two Pink Finishes at 88,000 Won
South Korean tobacco company KT&G launched the limited-edition lil HYBRID 3.0 Misty Rosé Edition II on September 30, 2026, following the original Misty Rosé Edition introduced in November 2025. The new release comes in two pink finishes, Bloom Rosé and Viva Rosé, each priced at 88,000 won. Both versions initially went on sale through the lil Store online shop and lil MINIMALIUM flagship stores. From October 7, Bloom Rosé became available at approximately 1,500 lil Station retail outlets nationwide. The release retains the existing lil HYBRID 3.0 hybrid heated tobacco platform, with changes focused on exterior design and distribution.
product
Oct.10
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11